Response to Different Wheat Genotypes in Not-celiac Wheat Sensitivity

Sponsor

University of Palermo (Other)

Overall Status

Recruiting

CT.gov ID

NCT03024775

Collaborator

(none)

Enrollment

Locations

Arms

76.9

Anticipated Duration (Months)

Patients Per Site

0.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

Condition or Disease	Intervention/Treatment	Phase
Non-celiac Wheat Sensitivity	Dietary Supplement: Wheat flour Dietary Supplement: Placebo	N/A

Detailed Description

Non-celiac gluten sensitivity (NCGS) is a condition where intestinal and extraintestinal symptoms are triggered by gluten ingestion in the absence of celiac disease and wheat allergy. Despite the great interest in NCGS, much remains unknown about the pathogenesis. Some studies seem to suggest that wheat components other than gluten (i.e. amylase/trypsine inhibitors, ATIs) can cause the symptoms, and therefore the term "non-celiac wheat sensitivity" (NCWS) has been proposed instead of NCGS. NCWS pathogenesis has been attributed to very different mechanisms: innate or adaptive immunity, incomplete digestion and/or absorption of fermentable oligosaccharides and disaccharides, monosaccharides and polyols, and, finally, psychological effect. In addition, it is believed that this condition is worldwide increasing, due to the evolution of wheat breeding (i.e. consumption of wheats with high gluten content), and that ancient wheats are better tolerated by NCWS patients than the modern ones. Therefore, the aim of the study is to determine whether the common belief regarding the fact that ancient wheats are better tolerated by NCWS patients than the modern ones is confirmed by scientific data, and to identify the wheat kernel components triggering this pathology. The availability of wheat materials with opposite characteristics, such as the period of development (ancient vs. modern), or the technological properties (cultivars with weak glutens vs. strong gluten), or the presence/absence of specific ATIs polypeptides, will allow to define the role played by these factors. The researchers take into consideration different tetraploid wheat genotypes derived from the Italian breeding activity carried out during the 20th century in comparison with landraces, primitive and old wheat cultivars previously cultivated and used mostly in Southern Italy for pasta and bread production, together with an experimental genetically modified (GM) wheat line expressing a lower amount of ATIs. For the purpose of the study, the collection has been subdivided into 5 groups, according to the breeding period. Wheat genotypes will be also evaluated for several parameters: protein content, gluten index, quantitative analysis of ATIs proteins by Mass Spectrometry, etc. The project has two objectives, related to the influence of wheat consumption on health: 1) extraction and testing of total kernel proteins, in order to evaluate the inflammatory response to gluten and non-gluten proteins by peripheral blood mononuclear cells (PBMC) and immunocytes extracted by the rectal mucosa of NCWS patients and healthy control subjects, and 2) clinically testing two wheat genotypes, selected on the basis of the previous in vitro studies, showing the highest and the lowest in vitro inflammatory response, in order to verify their effect in triggering NCWS symptoms.

Study Design

Study Type:

Interventional

Anticipated Enrollment :

50 participants

Allocation:

Randomized

Intervention Model:

Crossover Assignment

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Primary Purpose:

Other

Official Title:

Clinical Response and Cytokines Production After Challenge With Different Wheat Genotypes in Patients With Not-celiac Wheat Sensitivity.

Actual Study Start Date :

Jan 1, 2017

Anticipated Primary Completion Date :

Jan 1, 2023

Anticipated Study Completion Date :

Jun 1, 2023

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: Active Comparator 1 Wheat flour with high inflammatory response will be administered blindly versus placebo for 15 days in NCWS patients.	Dietary Supplement: Wheat flour Wheat flour will be administered three times per day for 15 days.
Active Comparator: Active Comparator 2 Wheat flour with low inflammatory response will be administered blindly versus placebo for 15 days in NCWS patients.	Dietary Supplement: Wheat flour Wheat flour will be administered three times per day for 15 days.
Placebo Comparator: Placebo 1 Placebo (xylose) will be administered blindly versus wheat flour with high inflammatory response for 15 days in NCWS patients.	Dietary Supplement: Placebo Placebo (xylose) will be administered three times per day for 15 days.
Placebo Comparator: Placebo 2 Placebo (xylose) will be administered blindly versus wheat flour with low inflammatory response for 15 days in NCWS patients.	Dietary Supplement: Placebo Placebo (xylose) will be administered three times per day for 15 days.

Outcome Measures

Primary Outcome Measures

Inflammatory response to wheat genotypes by PBMC of NCWS patients and healthy control subjects. [Through study completion, an average of 6 months]
Cytokines evaluation in response to gluten and non-gluten proteins from total kernel proteins of different wheat genotypes (i.e. ancient vs. modern vs. genetically modified) by PBMC of patients with a definitive diagnosis of NCWS, at the end of the diagnostic Double-Blind Placebo-Controlled (DBPC) wheat challenge, and of healthy control subjects.
Inflammatory response to wheat genotypes by rectal immunocytes of NCWS patients and healthy control subjects. [Through study completion, an average of 6 months]
Rectal immunocytes evaluation in response to gluten and non-gluten proteins from total kernel proteins of different wheat genotypes (i.e. ancient vs. modern vs. genetically modified) by immunocytes extracted by the rectal mucosa of patients with a definitive diagnosis of NCWS, at the end of the diagnostic Double-Blind Placebo-Controlled (DBPC) wheat challenge, and of healthy control subjects.

Secondary Outcome Measures

Clinical response to wheat genotypes in NCWS patients [Change from baseline at 2 weeks]
Symptoms evaluation before and after a 2 weeks challenge with two wheat genotypes showing the highest and the lowest in vitro inflammatory response in diagnosed NCWS patients on gluten-free diet. During the challenge periods, the severity of symptoms will be recorded: the patients will complete a 100mm visual analog scale, which assesses the specific symptoms they report. The challenges will be considered positive if the same symptoms which had been initially present will reappear after their disappearance on elimination diet.

Eligibility Criteria

Criteria

Ages Eligible for Study:

18 Years to 65 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

All the patients will meet the recently proposed criteria:

negative serum anti-tissue transglutaminase and antiendomysium (EmA) immunoglobulin (Ig)A and IgG antibodies
absence of intestinal villous atrophy
IgE-mediated immunoallergic tests negative to wheat (skin prick tests and/or serum specific IgE detection)
follow-up duration >12 months after the initial diagnosis
at least two outpatient visits during the follow-up period.

Adjunctive criteria adopted in our patients will be:

resolution of the gastrointestinal symptoms on a standard elimination diet, without wheat, cow's milk, egg, tomato, chocolate, or other food(s) causing self-reported symptoms
symptom reappearance on DBPC wheat challenge, performed as described previously. As in previous studies, DBPC cow's milk protein challenge and other "open" food challenges will be also performed.

Exclusion Criteria:

Exclusion criteria will be:

age <18 years
positive EmA in the culture medium of the duodenal biopsies, even if the villi to crypts ratio in the duodenal mucosa was normal
self-exclusion of wheat from the diet and refusal to reintroduce it before entering the study
other organic gastrointestinal diseases (i.e. careful exclusion of Crohn's disease)
concomitant treatment with steroids and/or antihistamines.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Department of Internal Medicine, Giovanni Paolo II Hospital of Sciacca	Sciacca	Agrigento	Italy	92019
2	Department of Internal Medicine, University Hospital of Palermo	Palermo		Italy	90129